Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Accumulated Expenses (2021 - 2025)

Prime Medicine's Accumulated Expenses history spans 5 years, with the latest figure at $12.6 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses fell 20.77% year-over-year to $12.6 million; the TTM value through Dec 2025 reached $12.6 million, down 20.77%, while the annual FY2025 figure was $12.6 million, 20.77% down from the prior year.
  • Accumulated Expenses reached $12.6 million in Q4 2025 per PRME's latest filing, up from $11.0 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $37.2 million in Q4 2021 to a low of $300000.0 in Q2 2023.
  • Average Accumulated Expenses over 5 years is $12.6 million, with a median of $11.0 million recorded in 2025.
  • Peak YoY movement for Accumulated Expenses: crashed 71.26% in 2022, then surged 3531.67% in 2024.
  • A 5-year view of Accumulated Expenses shows it stood at $37.2 million in 2021, then plummeted by 71.26% to $10.7 million in 2022, then skyrocketed by 32.02% to $14.1 million in 2023, then increased by 12.71% to $15.9 million in 2024, then dropped by 20.77% to $12.6 million in 2025.
  • Per Business Quant, the three most recent readings for PRME's Accumulated Expenses are $12.6 million (Q4 2025), $11.0 million (Q3 2025), and $12.2 million (Q2 2025).